Page last updated: 2024-08-26

carbidopa, levodopa drug combination and apomorphine

carbidopa, levodopa drug combination has been researched along with apomorphine in 23 studies

Research

Studies (23)

TimeframeStudies, this research(%)All Research%
pre-19902 (8.70)18.7374
1990's2 (8.70)18.2507
2000's2 (8.70)29.6817
2010's14 (60.87)24.3611
2020's3 (13.04)2.80

Authors

AuthorsStudies
Frankel, JP; Hughes, A; Lees, AJ; Stern, GM1
Carvey, P; Goetz, CG; Klawans, HL1
Casey, DE; Gerlach, J1
Blaney, TJ; Chandonait, SE; Emerich, DF; Lindner, MD; Mullins, TD; Plone, MA; Sherman, SS; Stott, JA; Winn, SR1
Ghika, J; Solida, A; Vingerhoets, F1
Ludin, HP; Surber, Ch1
Belavic, J1
Worth, PF1
Capone, JG; Contini, E; Golfre-Andreasi, N; Gragnaniello, D; Preda, F; Quatrale, R; Sensi, M; Sette, E; Tola, MR; Trevisani, L; Tugnoli, V1
Brauer, AF; Ciucci, MR; Kelm-Nelson, CA1
Bloem, BR; Faber, MJ; Nijhuis, FA; Post, B; van Heek, J1
Borgemeester, R; van Laar, T1
Evans, AH; Fung, VSC; Hayes, M; Iansek, R; Kimber, T; O'Sullivan, JD; Sue, CM; Williams, DR1
Aasly, J; Dietrichs, E; Egge, A; Ezat, B; Pihlstrøm, L; Tysnes, OB1
Mundt-Petersen, U; Odin, P1
Antonini, A; Canesi, M; Costanzo, AM; Defazio, G; di Luzio Paparatti, U; Gualberti, G; Latorre, A; Lopiano, L; Marano, P; Melzi, G; Modugno, N; Pontieri, FE; Quatrale, R; Sensi, M; Solla, P; Tambasco, N; Tessitore, A1
Eklund, M; Henriksen, T; Nyholm, D; Odin, P; Sahlström, T; Timpka, J1
Lees, AJ; Moro, A; Munhoz, RP; Pessoa, RR; Teive, HAG1
Centonze, D; Fasano, A; Femiano, C; Lena, F; Modugno, N; Olivola, E; Santilli, M; Varanese, S1
Bartig, D; Gold, R; Jörges, C; Jost, W; Krogias, C; Richter, D; Stumpe, B; Tönges, L1
McFarthing, K; Prakash, N; Simuni, T1
de Bie, RMA; Dijk, JM; Espay, AJ; Katzenschlager, R1
Comella, CL; Hauser, RA; LeWitt, PA1

Reviews

9 review(s) available for carbidopa, levodopa drug combination and apomorphine

ArticleYear
Animal models of tardive dyskinesia: their use in the search for new treatment methods.
    Modern problems of pharmacopsychiatry, 1983, Volume: 21

    Topics: Age Factors; Amphetamine; Animals; Antipsychotic Agents; Apomorphine; Carbidopa; Corpus Striatum; Disease Models, Animal; Dopamine; Drug Combinations; Drug Interactions; Dyskinesia, Drug-Induced; Guinea Pigs; Haloperidol; Haplorhini; Humans; Levodopa; Lithium; Male; Parasympatholytics; Rats; Receptors, Dopamine; Stereotyped Behavior

1983
[Prevention and treatment of fluctuations in patients with Parkinson's disease].
    Praxis, 2006, Dec-20, Volume: 95, Issue:51-52

    Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Catechol O-Methyltransferase Inhibitors; Deep Brain Stimulation; Dopamine Agonists; Drug Administration Routes; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Infusion Pumps, Implantable; Levodopa; Monoamine Oxidase Inhibitors; Neurologic Examination; Parkinson Disease; Treatment Outcome

2006
When the going gets tough: how to select patients with Parkinson's disease for advanced therapies.
    Practical neurology, 2013, Volume: 13, Issue:3

    Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Deep Brain Stimulation; Drug Combinations; Drug Delivery Systems; Humans; Levodopa; Parkinson Disease; Patient Selection

2013
The need for non-oral therapy in Parkinson's disease; a potential role for apomorphine.
    Parkinsonism & related disorders, 2016, Volume: 33 Suppl 1

    Topics: Animals; Antiparkinson Agents; Apomorphine; Carbidopa; Drug Administration Routes; Drug Combinations; Gels; Humans; Intestines; Levodopa; Parkinson Disease

2016
Practical approaches to commencing device-assisted therapies for Parkinson disease in Australia.
    Internal medicine journal, 2017, Volume: 47, Issue:10

    Topics: Antiparkinson Agents; Apomorphine; Australia; Carbidopa; Deep Brain Stimulation; Drug Combinations; Humans; Infusions, Parenteral; Infusions, Subcutaneous; Levodopa; Parkinson Disease

2017
Infusional Therapies, Continuous Dopaminergic Stimulation, and Nonmotor Symptoms.
    International review of neurobiology, 2017, Volume: 134

    Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Dopamine; Dopamine Agents; Dopamine Agonists; Drug Combinations; Humans; Infusion Pumps, Implantable; Infusions, Intravenous; Infusions, Subcutaneous; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic

2017
Apomorphine in the treatment of Parkinson's disease: a review.
    Arquivos de neuro-psiquiatria, 2018, Volume: 76, Issue:12

    Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Deep Brain Stimulation; Dopamine Agonists; Drug Combinations; Humans; Levodopa; Parkinson Disease

2018
The Choice Between Advanced Therapies for Parkinson's Disease Patients: Why, What, and When?
    Journal of Parkinson's disease, 2020, Volume: 10, Issue:s1

    Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Clinical Decision-Making; Deep Brain Stimulation; Dopamine Agents; Drug Combinations; Humans; Infusions, Subcutaneous; Levodopa; Parkinson Disease

2020
On demand therapy for Parkinson's disease patients: Opportunities and choices.
    Postgraduate medicine, 2021, Volume: 133, Issue:7

    Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Dopamine Agonists; Drug Administration Routes; Drug Combinations; Humans; Levodopa; Parkinson Disease

2021

Other Studies

14 other study(ies) available for carbidopa, levodopa drug combination and apomorphine

ArticleYear
Marijuana for parkinsonian tremor.
    Journal of neurology, neurosurgery, and psychiatry, 1990, Volume: 53, Issue:5

    Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Diazepam; Drug Combinations; Humans; Levodopa; Marijuana Smoking; Parkinson Disease; Tremor

1990
Dopamine agonists in clinical research for new tardive dyskinesia treatments.
    Modern problems of pharmacopsychiatry, 1983, Volume: 21

    Topics: Adult; Aged; Antipsychotic Agents; Apomorphine; Benserazide; Carbidopa; Dopamine; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Hydrazines; Levodopa; Middle Aged; Synaptic Transmission

1983
Somatic delivery of catecholamines in the striatum attenuate parkinsonian symptoms and widen the therapeutic window of oral sinemet in rats.
    Experimental neurology, 1997, Volume: 145, Issue:1

    Topics: Administration, Oral; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Carbidopa; Cell Transplantation; Disease Models, Animal; Dopamine; Drug Combinations; Drug Synergism; Levodopa; Male; Movement Disorders; Neostriatum; Parkinson Disease, Secondary; PC12 Cells; Rats; Rats, Sprague-Dawley; Rotation

1997
Acute dopaminergic challenge tests to assess postural/kinetic tremor of different origin: a case report.
    Journal of neurology, neurosurgery, and psychiatry, 2002, Volume: 73, Issue:2

    Topics: Aged; Antiparkinson Agents; Apomorphine; Carbidopa; Dose-Response Relationship, Drug; Drug Combinations; Electromyography; Essential Tremor; Female; Humans; Levodopa; Neurologic Examination; Parkinson Disease; Posture; Receptors, Dopamine

2002
Drugs for treating Parkinson disease.
    Nursing, 2012, Volume: 42, Issue:7

    Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Catechols; Drug Combinations; Drugs, Generic; Humans; Indans; Levodopa; Nitriles; Parkinson Disease

2012
Emerging issues on selection criteria of levodopa carbidopa infusion therapy: considerations on outcome of 28 consecutive patients.
    Journal of neural transmission (Vienna, Austria : 1996), 2014, Volume: 121, Issue:6

    Topics: Aged; Amantadine; Antiparkinson Agents; Apomorphine; Carbidopa; Caregivers; Drug Administration Routes; Drug Combinations; Drug Delivery Systems; Female; Follow-Up Studies; Humans; Levodopa; Male; Mental Status Schedule; Middle Aged; Parkinson Disease; Patient Selection; Retrospective Studies; Severity of Illness Index; Statistics, Nonparametric; Surveys and Questionnaires; Treatment Outcome

2014
Vocal training, levodopa, and environment effects on ultrasonic vocalizations in a rat neurotoxin model of Parkinson disease.
    Behavioural brain research, 2016, 07-01, Volume: 307

    Topics: Animals; Antiparkinson Agents; Apomorphine; Carbidopa; Communication Disorders; Disease Models, Animal; Dopamine; Dopamine Agonists; Drug Combinations; Fourier Analysis; Levodopa; Male; Neurotoxins; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Long-Evans; Stereotyped Behavior; Time Factors; Ultrasonics; Vocalization, Animal

2016
Choosing an Advanced Therapy in Parkinson's Disease; is it an Evidence-Based Decision in Current Practice?
    Journal of Parkinson's disease, 2016, 07-25, Volume: 6, Issue:3

    Topics: Apomorphine; Carbidopa; Caregivers; Clinical Decision-Making; Consumer Health Information; Deep Brain Stimulation; Dopamine Agonists; Drug Combinations; Evidence-Based Practice; Humans; Levodopa; Neurologists; Parkinson Disease; Patient Preference; Qualitative Research

2016
Use of advanced therapies for Parkinson's disease in Norway.
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2017, Volume: 137, Issue:9

    Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Deep Brain Stimulation; Drug Combinations; Drug Utilization; Gels; Healthcare Disparities; Humans; Infusions, Parenteral; Levodopa; Norway; Parkinson Disease; Patient Education as Topic

2017
Caregiver burden and its related factors in advanced Parkinson's disease: data from the PREDICT study.
    Journal of neurology, 2018, Volume: 265, Issue:5

    Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Apomorphine; Carbidopa; Caregivers; Cost of Illness; Cross-Sectional Studies; Drug Combinations; Family; Female; Humans; Italy; Levodopa; Male; Middle Aged; Parkinson Disease; Patient Satisfaction; Quality of Life; Socioeconomic Factors; Surveys and Questionnaires; Treatment Outcome

2018
Workforce participation and activities in Parkinson's disease patients receiving device-aided therapy.
    Acta neurologica Scandinavica, 2018, Volume: 138, Issue:1

    Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Apomorphine; Carbidopa; Deep Brain Stimulation; Denmark; Drug Combinations; Female; Gels; Humans; Intestines; Levodopa; Male; Middle Aged; Parkinson Disease; Pilot Projects; Retrospective Studies; Sweden

2018
Continuous subcutaneous apomorphine infusion in Parkinson's disease: causes of discontinuation and subsequent treatment strategies.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2019, Volume: 40, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Apomorphine; Carbidopa; Cognitive Dysfunction; Deep Brain Stimulation; Dopamine Agonists; Drug Combinations; Drug Substitution; Electronic Health Records; Female; Humans; Infusions, Subcutaneous; Levodopa; Male; Medication Adherence; Middle Aged; Parkinson Disease; Retrospective Studies

2019
Dynamics of device-based treatments for Parkinson's disease in Germany from 2010 to 2017: application of continuous subcutaneous apomorphine, levodopa-carbidopa intestinal gel, and deep brain stimulation.
    Journal of neural transmission (Vienna, Austria : 1996), 2019, Volume: 126, Issue:7

    Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Deep Brain Stimulation; Drug Combinations; Gels; Germany; Humans; Infusions, Parenteral; Infusions, Subcutaneous; Levodopa; Neurology; Parkinson Disease; Practice Patterns, Physicians'

2019
Clinical Trial Highlights - Infusion Therapies.
    Journal of Parkinson's disease, 2020, Volume: 10, Issue:1

    Topics: Apomorphine; Carbidopa; Clinical Trials as Topic; Dopamine Agonists; Drug Combinations; Gels; Humans; Infusion Pumps, Implantable; Infusions, Subcutaneous; Jejunum; Levodopa; Parkinson Disease

2020